Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Amyloid beta-protein (Aβ42) (Aβ42)
- Target
- Aβ42
- Molecular classification
- Peptide, Proteolytic fragment
01
Overview
Amyloid beta-protein (Aβ42) is a 42-amino acid peptide derived from the amyloid precursor protein (APP). It is a major component of amyloid plaques found in the brains of Alzheimer's disease patients and is implicated in the pathogenesis of the disease due to its neurotoxic properties and ability to aggregate. Aβ42 levels in cerebrospinal fluid and blood are used as biomarkers for Alzheimer's disease diagnosis and monitoring. It is considered a therapeutic target for Alzheimer's disease, and drug development focuses on inhibiting its aggregation and promoting its clearance.
- Other names
- Amyloid beta 1-42Abeta 42AB42Amyloid beta peptide 42
02
Mechanism of action
Inhibition of aggregation; promotion of clearance
03
Biological functions
Amyloid plaque formationNeurotoxicityCell death
04
Disease associations
Alzheimer's diseaseNeurodegenerative disease
05
Safety considerations
Potential for off-target effectsImmune-related adverse events
06
Biomarkers
Cerebrospinal fluid (CSF) Aβ42 levelsPlasma Aβ42 levelsAβ42/Aβ40 ratio
Beyond the preview
Go deeper on Amyloid beta-protein (Aβ42) (Aβ42).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amyloid beta-protein (Aβ42) (Aβ42).